我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

慢性肾脏病高血压联合降压:自由联合 还是固定配方制剂?(PDF)

《医学争鸣》[ISSN:1000-2790/CN:61-1060/R]

期数:
2019年04期
页码:
44-47
栏目:
学术争鸣
出版日期:
2019-08-26

文章信息/Info

Title:
Free combination or fixed-dose combination agents against hypertension with chronic kidney disease?
作者:
毕礼明朱冬云陆 曙
( 江苏省无锡市中医医院,江苏 无锡 214071)
Author(s):
BI Liming ZHU Dongyun LU Shu
Department of Nephrology, Wuxi Hospital of Chinese Medicine, Wuxi 214071, China
关键词:
高血压慢性肾脏病自由联合固定配方制剂
Keywords:
hypertension CKD free combination fixed-dose combination agents
分类号:
R54
DOI:
10.13276/j.issn.1674-8913.2019.04.010
文献标识码:
A
摘要:
慢性肾脏病(CKD)患者的血压达标是<130/80 mmHg,常常需要2种或者以上的抗高血压药物联合 使用,而且CKD患者降低血压的同时还需要减少蛋白尿以带来肾脏获益。目前市场上有固定的联合降压药物,也 可以根据医生处方进行自由联合,然而2018年欧洲高血压指南推荐优先选择固定配方的降压药物。这个建议是否 适合CKD患者值得探讨。
Abstract:
The target of antihypertension in the patients with chronic kidney disease (CKD) and hypertension is less than 130/80 mmHg, which is usually realized by the combined use of two or more antihypertensive medications. Furthermore, the reduction of blood pressure should be accompanied by the decrease of proteinuria to maximize the potential benefits to the kidney. There are some fixed-dose antihypertension medications in the current market. The patients can choose free combination medications according to doctors’ suggestions as well. However, 2018 ESC/ESH Guidelines for the management of arterial hypertension suggest choosing fixed-dose combination agents firstly. It is necessary to discuss whether the suggestion is suitable for CKD.

参考文献/References

[1] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. Eur Heart J, 2018, 39(33):3021-3104.
[2] Zheng Y, Cai GY, Chen XM, et al. Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients[J]. Chin Med J (Engl), 2013, 126(12):2276-2280.
[3] 中国高血压防治指南修订委员会. 中国高血压防治指 南[J]. 中华高血压杂志, 2011, 19(8):701-743.
[4] Zhang F, Liu H, Liu D, et al. Effects of RAAS inhibitors in patients with kidney disease[J]. Curr Hypertens Rep, 2017, 19(9):72.
[5] Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency[J]. N Engl J Med, 2006, 354(2):131-140.
[6] Hou FF, Xie D, Zhang X, et al. Renoprotection of optimal antiproteinuric doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency[J]. J Am Soc Nephrol, 2007, 18(6):1889-1898.
[7] Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study[J]. BMJ, 2017, 356:j791.
[8] Feldman RD, Liu L, Wu Z, et al. Hypertension attitude perspectives and needs (HAPPEN): a real-world survey of physicians and patients with hypertension in China[J]. J Clin Hypertens (Greenwich), 2017, 19(3):256-264.
[9] Angeli F, Reboldi G, Mazzotta G, et al. Fixed-dose combination therapy in hypertension: cons[J]. High Blood Press Cardiovasc Prev, 2012, 19(2):51-54.
[10] 中国医师协会肾脏内科医师分会. 中国肾性高血压管理 指南2016[J]. 中华医学杂志, 2017, 97(20):1547-1555.
[11] Kario K, Chen CH, Park S, et al. Consensus document on improving hypertension management in Asian patients, taking into account Asian characteristics[J]. Hypertension, 2018, 71(3):375-382.
[12] De Nicola L, Gabbai FB, Agarwal R, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients[J]. J Am Coll Cardiol, 2013, 61(24):2461-2467.
[13] Sackett DL, Rosenberg WM, Gray JA, et al. Evidence-based medicine: what it is and what it isn’t[J]. Clin Orthop Relat Res, 2007, 455:3-5.
[14] Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations[J]. J Manag Care Pharm, 2006, 12(3):239-245.
[15] Claxton AJ, Cramer J, Pierce C, et al. A systematic review of the associations between dose regimens and medication compliance[J]. Clin Ther, 2001, 23(8):1296-1310.
[16] Xie L, Frech-Tamas F, Marrett E, et al. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy[J]. Curr Med Res Opin, 2014, 30(12):2415-2422.
[17] Zeng F, Patel BV, Andrews L, et al. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens[J]. Curr Med Res Opin, 2010, 26(12):2877-2887.
[18] Tung YC, Lin YS, Wu LS, et al. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan[J]. J Clin Hypertens (Greenwich), 2015, 17(1):51-58.
[19] Januszko-Giergielewicz B, Kubiak M, Gromadziński L. The role of combination therapy in the management of hypertension in patients with chronic kidney disease[J]. Przegl Lek, 2013, 70(4):199-204.
[20] Weir MR. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease[J]. Am J Hypertens, 2005, 18(4 Pt 2):100S-105S.

备注/Memo

备注/Memo:
基金项目:江苏省无锡市医院管理中心课题(YGZXM1549)
通信作者:陆 曙。Tel:0510-88859999, E-mail:lushu@medmail.com.cn
作者简介:毕礼明。博士,副主任中医师。研究方向:中西结合治疗慢性肾脏病。Tel:13601487018,E-mail:biliming00@aliyun.com
更新日期/Last Update: 2019-08-26